Vet Clin Path Journal http://vetclinpathjournal.org/ Mon, 10 Jan 2022 03:19:21 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://vetclinpathjournal.org/wp-content/uploads/2021/05/cropped-icon-32x32.png Vet Clin Path Journal http://vetclinpathjournal.org/ 32 32 Private Vet College Fee Rise: Haryana ACS Orders Investigation Amid Different Positions https://vetclinpathjournal.org/private-vet-college-fee-rise-haryana-acs-orders-investigation-amid-different-positions/ Sun, 09 Jan 2022 23:46:25 +0000 https://vetclinpathjournal.org/private-vet-college-fee-rise-haryana-acs-orders-investigation-amid-different-positions/

Almost three years after a committee set up by the Haryana government recommended an increase in tuition fees for private veterinary colleges, three more officers of the rank of chief secretary (ACS) in the livestock department have taken as many divergent positions on the new fee structure, according to official documents.

Initially in its ordinance of October 22, 2019, the ACS (Department of Livestock and Dairy Production) at the time, Sunil K Gulati, refused to accept the recommendations of the three-member panel that the director general of the ‘breeding had set up on March 22, 2019, to review the fee structure.

Later, Raja Sekhar Vundru, who is now an ACS Rank Officer, took care of the matter while he was in post as Principal Secretary (Breeding). Vundru, in a seven-page order on December 16, 2020, confirmed the fee schedule the committee recommended on July 29, 2019.

And now, in a final round, Ankur Gupta, when appointed ACS (breeding), appointed retired IAS officer OP Langayan on December 23, 2021 to conduct a preliminary investigation against three officials of the management who had recommended an increase in fees. The ACS Gupta order states that preliminary examination was ordered on two complaints from Dr Sandeep Kumar Gupta, senior scientist at Lala Lajpat Rai University of Veterinary and Animal Sciences (LUVAS), Hisar.

“I have been ordered by the government to investigate the issue of the fee hike in question. Very soon I will be issuing the advisories, ”said Langayan, IAS (retd), when contacted.

Litigation Commission

The state government received a request in February 2019 to review the fee structure. A three-member committee was set up on March 22 to review the fee structure for unassisted private colleges offering bachelor’s of veterinary science and animal husbandry degrees.

According to a decree of the Director General (Livestock and Dairy Production) of March 22, the state government ordered a review of the annual fee structure of private colleges offering bachelor’s programs in veterinary science and breeding. A committee made up of three senior management officers – OP Chhikara, co-director (administration), Pardeep Chauhan, responsible for credit planning, and Kuldeep Singh, account manager – has been set up. The panel was invited to review the structure of the curriculum fee structure of the International Institute for Veterinary Education and Research (IIVR), Bahu Akbarpur, Rohtak / state private institutions.

According to official records, the panel submitted a report on July 30, recommending that “the fee structure of the private veterinary college / IIVR should be revised.”

The recommended tuition structure committee for the 2019-2020 batch of students has been ??3.49 lakh (state quota), ??5.75 lakh (management quota) and US $ 88,000 (NRI quota).

Divergent positions

“I have reviewed the tariff structure of IIVER, Bahu Akbarpur, Rohtak, as decided from time to time by the Haryana State Government and the proposed revision of the same recommended by the committee, and I am not not agree with the recommendations of the committee ”, then indicated ACS Sunil K Gulati in his order of October 22, 2019.

His order further stated that the state government should not lose sight of the previous decision of the ACS-led (breeding) committee which, on December 15, 2016, changed the fee structure and mentioned that “the fee structure, if deemed necessary, will be reviewed every two years on the basis of the price index in effect at that time.

ACS Gulati pointed out that perhaps the current committee inadvertently did not delve into the subject.

After the resignation of ACS Gulati, the case was taken over by Raja Sekhar Vundru, principal secretary (breeding).

According to an order issued on December 16, 2020 by Vundru, a petition has been filed with the High Court asking the government of Haryana to increase the annual fees for BVSc and AH courses as approved by the relevant authority.

The High Court had dismissed the petition and “quashed the order of 22.10.2019 regarding the fixing of costs” and ordered the government of Haryana to “issue a new order after hearing the petitioner”.

“After hearing the petitioner (…) and after careful consideration of all relevant issues, the petition is accepted. The price list set by the departmental committee of 07.29.2019 … is maintained … “, ordered ACS Vundru in December 2020.

However, a year later, ACS (breeding) Ankur Gupta, on December 23, 2021, issued an order appointing OP Langayan, a retired IAS officer, to conduct the preliminary investigation.

“The governor of Haryana is further pleased to appoint the dean of the veterinary science faculty of LUVAS, Hisar, as the presenting officer in this investigation,” the order said, directing the group led by Langayan to submit the report. investigation to the government as soon as possible.


]]>
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop New Patented Molecular Signatures for Biologic Therapeutic Breeding in Rheumatoid Arthritis https://vetclinpathjournal.org/exagen-inc-and-queen-mary-university-of-london-announce-exclusive-license-and-collaboration-to-develop-new-patented-molecular-signatures-for-biologic-therapeutic-breeding-in-rheumatoid-arthritis/ Sun, 09 Jan 2022 17:00:00 +0000 https://vetclinpathjournal.org/exagen-inc-and-queen-mary-university-of-london-announce-exclusive-license-and-collaboration-to-develop-new-patented-molecular-signatures-for-biologic-therapeutic-breeding-in-rheumatoid-arthritis/

SAN DIEGO, January 09, 2022 (GLOBE NEWSWIRE) – Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University in London, today announced the signature of a research collaboration and an exclusive license agreement. The collaboration will focus on the development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize the selection of therapeutic agents for patients with rheumatoid arthritis. (PR). Both parties will contribute to the development of patent-pending tests, leading to the commercialization of new molecular tests that segment patients based on gene expression in their synovial tissue biopsies.

RA is estimated to affect approximately two million patients in the United States and is twice as common in women as in men and may be difficult to manage due to the variability in response to treatment of an patient to another. The selection of therapeutic agents for patients with RA remains a significant unmet need. Patients with RA often try several therapies empirically before finding one that decreases the activity of their disease. Placing a patient with RA on ineffective therapy risks advancing and aggravating the disease, further damaging the joints, and wasting a great deal of expense on expensive therapeutic agents. There is currently no reliable test to predict a positive patient response prior to the selection of commonly prescribed biological therapeutic agents.

Based on Professor Costantino Pitzalis and Dr Myles Lewis’s definition of molecular pathology of disease course and response to treatment, Exagen has acquired an exclusive worldwide license for a family of patent-pending tests relating to RNA expression models used in predicting patient response to prescribed csDMARDs and biologic therapies for RA. The tests use minimally invasive synovial tissue biopsies as input, which are then evaluated for RNA expression data. This data is then processed by proprietary algorithms that provide actionable information about the predicted csDMARD and the biological therapeutic response for patients with RA based on the RNA expression patterns of an individual patient.

Professor Pitzalis, Professor of Rheumatology in Arthritis and Deputy Director of the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry at Queen Mary University in London, said: “I am delighted to be a part of this research collaboration with Exagen and I look forward to contributing to the development of diagnostics aimed at integrating molecular pathology into clinical algorithms to better define specific pathways leading to disease diversity in individual patients. This would better inform clinicians about patient prognosis and improve their ability to make informed decisions about prescribing drugs. Exagen’s track record in bringing diagnostics to market takes this opportunity to a whole new level, bringing the promise of precision medicine closer to clinical implementation.

Professor Pitzalis is a leading authority on rheumatoid arthritis. He leads a team of 50 clinical researchers and is the author of over 300 peer-reviewed publications in the field of inflammation, immunity and arthritis. Professor Pitzalis formulated this revolutionary approach to gene expression models with Dr Myles Lewis, head of the bioinformatics / biostatistics group at the Center for Experimental Medicine and Rheumatology. “We are delighted to be working with Professor Pitzalis and Dr Lewis of Queen Mary University in London to accelerate the development of their highly innovative RNA-based biomarker assays to better serve patients with RA. Professor Pitzalis is a well-respected thought leader in arthritis research, and Exagen looks forward to working with his group to deliver exciting and revolutionary products to improve the continuum of care for patients with the disease. rheumatoid arthritis, ”said Ron Rocca, President and CEO of Exagen Inc.“ Exagen is committed to developing and commercializing these tests to inform treatment decisions throughout the patient’s journey with RA. We intend to market the new tests under the name AVISE® RADR (Rheumatoid Arthritis Drug Response).

For more information on AVISE® RADR, please visit https://exagen.com/tests/avise-radr/.

About Exagen inc.

Exagen is dedicated to transforming the continuum of care for patients with debilitating and chronic autoimmune diseases by enabling rapid differential diagnosis and optimizing therapeutic intervention. Exagen has developed and markets a portfolio of innovative test products under its AVISE® brand, many of which are based on our proprietary Cell-Bound Complement Activation Products technology, or CB-CAPs. Exagen’s goal is to enable providers to improve patient care through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune diseases, including rheumatoid arthritis and lupus. For more information, please visit www.exagen.com.

About Queen Mary University of London and Queen Mary Innovation Ltd

Queen Mary University of London is a leading research intensive university with over 28,000 students representing over 160 nationalities.

A member of the prestigious Russell Group, we work in the humanities and social sciences, medicine and dentistry, as well as science and engineering, with inspiring teaching directly informed by our research.

In the most recent Research Excellence Framework, we were ranked 5th nationally for the proportion of research results that were world-class or internationally excellent. We offer more than 240 degree programs and our reputation for excellent teaching has been recognized with a silver medal in the 2017 Teaching Excellence Framework (TEF) awards.

Queen Mary Innovation Ltd (QMI) is Queen Mary’s wholly owned technology transfer company and is responsible for the commercialization and management of the University’s intellectual property and portfolio of spin-off companies. QMI protects and exploits the intellectual property derived from Queen Mary’s research and helps to maximize the economic and societal impact of this research. QMI Biopharma’s Associate Director of Marketing, Dr. Michele Hill-Perkins, led the negotiation and licensing transaction for QMUL.

For more information on QMI, please visit http://www.qminnovation.co.uk.

Forward-looking statements

Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of collaboration with Queen Mary University, London and any potential development and commercialization of new patented molecular signatures for the diagnosis, prognosis and surveillance of diseases. autoimmune. The inclusion of forward-looking statements should not be taken as a representation by Exagen that any of its plans will be realized. Actual results may differ from those presented in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the development of new molecular signatures involves a long and complex process, and the collaboration may not lead to new patented molecular signatures or generate significant commercial test products in a timely manner, or not at all; the COVID-19 pandemic may continue to negatively affect our business, financial condition and results of operations, including our collaboration and development activities; risks associated with maintaining the collaboration and license agreement; and other risks described in previous Company press releases and documents filed by Exagen with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s annual report on Form 10-K and any subsequent filing with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen makes no commitment to update such statements to reflect events that occur or circumstances that occur. exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations
Exagen inc.
Ryan douglas
rdouglas@exagen.com
760.560.1525

Society
Exagen inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514

Source link

]]>
Op-Ed: The Right-Wing Mindset of Today’s Conspiracy Theory Goes Back to the John Birch Society https://vetclinpathjournal.org/op-ed-the-right-wing-mindset-of-todays-conspiracy-theory-goes-back-to-the-john-birch-society/ Sun, 09 Jan 2022 11:00:12 +0000 https://vetclinpathjournal.org/op-ed-the-right-wing-mindset-of-todays-conspiracy-theory-goes-back-to-the-john-birch-society/

If you are looking for the roots of the current bizarre conspiracy and anger-driven politics, you have to look beyond Donald Trump’s presidency or even the rise of social media or talk radio – back to accusers, arsonists, rhetoric far-fetched John Birch Society in the 1960s and 1970s.

It’s starting to fade into history, but the John Birch Society was once the most formidable anti-Communist organization of the Cold War era. Named after a U.S. Army captain killed by Chinese Communists, it was founded in 1958 by North Carolina-born candy tycoon Robert Welch. (His company created the caramel “Sugar Daddy” on a stick.) Most Americans heard of the company after March 20, 1961, when it was widely reported that Welch called former President Eisenhower a communist. .

It was an outrageous and ridiculous claim, but Welch was just beginning to weave his paranoia tapestry. He saw Communist plots hiding in middle schools, high schools and the government.

Fluoride was used to piss off Americans before the coming Communist occupation, he said.

Welch also called the civil rights movement a communist conspiracy.

Welch’s plots fueled postwar America’s growing distrust of government and its belief in top cover-ups. He had a particular influence in California, which played an inordinate role in the growth of the John Birch Society.

With epicenters in Orange County and Los Angeles, the California Birchers helped secure the loss of governor Richard Nixon in 1962, the Republican presidential nomination of Barry Goldwater in 1964, and victory in office. from Governor Ronald Reagan in 1966. Several members of Congress in California were Birchers, including Representatives Edgar Hiestand and John Rousselot, both of whom represented parts of Los Angeles County.

Over the years, Welch’s theories have grown wilder. He eventually concluded that communism was just another name for the conspiracy started by the Bavarian Illuminati in 1776. He also said that the Trilateral Commission, the Council on Foreign Relations and the Bilderbergers (a group that sought to fostering dialogue between Europe and North America) were the puppeteers of the foreign and economic interests of the United States. The company also called on the United States to withdraw from the United Nations and remove Chief Justice Earl Warren from office.

In the 1970s, the John Birch Society became even more influential. Despite a widespread belief that William F. Buckley’s “responsible” right wing had purged the Conservative Bircher movement, Welch was never excommunicated. His style of American conservatism has remained strong.

During these years Welch broadened the reach of society by opposing abortion, high taxes, and sex education – issues that propelled the Reagan Revolution. Bircher Lewis Uhler was instrumental in passing Proposition 13 to lower California property taxes in 1978.

All the while, Welch continued to argue his extreme theories.

In the 1970s, Americans began to receive confirmation that conspiracies might not be as rare and crazy as they seemed. In 1973 and 1974, Watergate demonstrated that a president could secretly abuse his constitutional authority. The Americans learned that more government officials had spied for the Soviet Union and worked with mobsters in a futile effort to kill a foreign head of state. The CIA was found to have carried out LSD experiments on Americans. After a while, everything seemed plausible. In the years that followed, the number of people who said they trusted the government plummeted.

Welch matters today because from the 1980s and beyond his world became ours. The depth of his influence in transforming the Republican Party – and therefore America – has never been fully appreciated. His political style remained extremely powerful after his death in 1985.

Reagan espoused conspiracy theories, such as his claim that Gerald Ford organized assassination attempts against himself to gain sympathy votes. In the 1990s, partisanship became more central, ideology more crucial. On the radical fringes of the far right, private militiamen have armed themselves to the teeth. Both major parties, they said, wanted to end US sovereignty. After the sieges of Ruby Ridge and Waco in 1992 and 1993, the militia movement became even more conspiratorial.

It wasn’t until a few years later, in 1996, that Alex Jones launched his conspiratorial radio show “The Final Edition”. Jones claimed the government planned the Oklahoma City bombings in 1995 and plotted to assassinate Branch Davidians in Waco. Rush Limbaugh’s attacks on Bill and Hillary Clinton were in the same vein. Hillary covered up the murder of Vince Foster, suggested Limbaugh.

On the afternoon of September 11, 2001, Jones declared that “every act of terrorism that we have reviewed, from the World Trade Center, from Oklahoma City to Waco, was government action.” In 2006, at least a third of Americans believed their government planned or allowed the 9/11 attacks to happen. And conspiracy theories started to flourish on the new social media sites: Facebook. Youtube. Twitter. The facts have not been verified.

Tea Party members argued that a globalist conspiracy caused the economic downturn. In 2012, Donald Trump tweeted “an extremely credible source … told me @BarackObama’s birth certificate is a fraud.” In 2015, Trump was a presidential candidate.

And so it continues. Welsh logic and Welsh rhetoric have taken over much of the right with false myths tempting the weak mind. More than two-thirds of Republicans still don’t believe Joe Biden won the 2020 election. The QAnon conspiracy theory – which argues that Democrats in the so-called deep state undermined Trump to cover up their child sex racket – has at least one member of the Congress.

Millions of Americans will not take vaccines to prevent COVID-19 because they don’t trust the science.

Today we are all stuck in the roller coaster of Robert Welch’s political imagination, and we can’t take it anymore.

Edward H. Miller is Associate Professor at Northeastern University and author of the forthcoming book A Life of Conspiracy: Robert Welch, the John Birch Society, and the Revolution of American Conservatism.

Source link

]]>
Gottheimer calls on governor to take essential action to protect New Jersey from Omicron and combat impacts on communities, hospitals, families and students https://vetclinpathjournal.org/gottheimer-calls-on-governor-to-take-essential-action-to-protect-new-jersey-from-omicron-and-combat-impacts-on-communities-hospitals-families-and-students/ Sun, 09 Jan 2022 00:02:00 +0000 https://vetclinpathjournal.org/gottheimer-calls-on-governor-to-take-essential-action-to-protect-new-jersey-from-omicron-and-combat-impacts-on-communities-hospitals-families-and-students/

Gottheimer calls on governor to take essential action to protect New Jersey from Omicron and combat impacts on communities, hospitals, families and students

Visit Holy Name Medical Center test site in Teaneck

Thank you to frontline healthcare workers

GLEN ROCK, NJ – US Congressman Josh Gottheimer (NJ-5) calls on Gov. Phil Murphy to take essential action to help the state tackle the current outbreak of COVID-19 Omicron and its impacts on hospital staff, families, students and communities.

Gottheimer asks Governor Murphy to:

  1. Alleviating hospital staff shortages by allowing recently retired healthcare professionals to have their licenses temporarily reactivated and by allowing certain providers to help, where most needed, outside of their regular scope of practice;
  2. Further use the New Jersey National Guard to expand COVID-19 testing capacity in our hardest hit communities; and
  3. Continue vital efforts to keep schools safe and open for in-person education.

Today, Gottheimer visited the COVID-19 testing site at Holy Name Medical Center in Teaneck to emphasize the importance of getting tested, to raise awareness of testing options in the Fifth District, and to thank first-aid health workers. line for their hard work. Gottheimer was joined by the Mayor of Teaneck, James Dunleavy, Nancy Palamara, Pharm.D, Vice President, Diagnostics and Therapeutics at Holy Name Medical Center, and Edward Torres, Executive Director, Pathology and Laboratory Medicine at Holy Name Medical Center. .

“In the weeks following November 30, when public health officials first identified the Omicron variant as a ‘variant of concern,’ Americans saw the rapid spread of the new variant and its ability to escape. vaccination. […] As a result of my discussions with Fifth District constituents and North Jersey public health officials, I believe there are several additional steps your administration can take to mitigate the impact of the Omicron variant, ” Congressman Josh Gottheimer wrote in a letter to Governor Phil Murphy this week. “By taking the additional measures described here, we can reduce the impact of the Omicron variant and minimize the disruption it will cause in the weeks to come.”

The full text of the letter can be found here and below:

January 7, 2022

The Honorable Phil Murphy

Governor, State of New Jersey

Governor’s office

P.O. Box 001

Trenton, New Jersey 08625

Dear Governor Murphy:

In the weeks following November 30, when public health officials first identified the Omicron variant as a “variant of concern,” Americans saw the rapid spread of the new variant and its ability to escape. the vaccination. I commend you for the State of New Jersey’s swift response to this new phase of the pandemic, including your work to ensure that New Jersey residents remain vigilant with vaccinations and mask wear.

However, additional actions are necessary to better equip our communities to manage this variant. Several steps could be immediately beneficial: (1) extend the flexibility of the license to practice and the scope of practice for front-line workers in order to increase the supply of qualified providers; (2) further use of the New Jersey National Guard to expand COVID-19 testing; and (3) continue your efforts to keep schools open – not only for the continuity of education, but also because of the implications of school closings on child care, which would further exacerbate the challenges facing our workers. essentials are faced.

You quickly prepared New Jersey for the Omicron variant. Since the beginning of December, when authorities detected the first case of Omicron in the state, you have called on the people of Jersey to get vaccinated, boosted and wear masks to reduce the spread of COVID-19. Over the past few days, you have worked alongside the Centers for Disease Control and Prevention to increase community access to testing in underserved areas of our state. These steps, coupled with the groundbreaking work of the New Jersey life sciences industry to bring cutting-edge therapeutics to market, have strengthened the foundation we now have to fight the current wave of this pandemic.

Despite all of this progress, as a result of my discussions with Fifth District constituents and North Jersey public health officials, I believe there are several additional steps your administration can take to mitigate the impact of the Omicron variant. First, the hospital systems in my district face immediate staffing shortages due to high infection rates among frontline workers. I was delighted to see your administration’s request this week for Federal Emergency Management Agency (FEMA) “strike teams” to be deployed to New Jersey to address systems staff burnout. crucial hospitals. Additionally, I encourage your administration to extend the recently expired license and scope of practice flexibilities of your Executive Order (EO) 112, issued at the onset of the pandemic. As you know, this EO has taken various steps to increase the availability of frontline health professionals. Unfortunately, with the rise of the Omicron wave, these steps are needed again.

Second, as you know, hospital systems in my district have been hit hard in recent days by the wave of testing, as schools, workplaces, travel destinations and other public accommodation demand the proof of a negative COVID-19 test. Due to the difficulty for many of my constituents to access rapid home tests, hospital emergency departments were faced with an onslaught of otherwise healthy people coming to the emergency department looking for of a COVID-19 test. This event reflects the demand for greater accessibility of tests. It also affects the entire health care system, making it difficult for people in urgent need of treatment to get the care they need. While waiting for additional rapid home tests to be dispatched, I encourage you to make further use of the New Jersey National Guard to expand COVID-19 testing capacity in our hardest hit communities.

Finally, I was delighted with your administration’s rollout on January 1 of a “test-to-stay” program for K-12 schools in New Jersey. As a result, more students will stay in school and receive in-person instruction by a combination of contact tracing and frequent testing. As you have recognized, in-person education, where possible, and the resulting benefits for our children are far preferable to distance learning. Without in-person education, many parents face the difficult choice of continuing to work or staying home to care for their children. Indeed, hospital administrators in North Jersey have told me about the importance of in-person instruction to prevent further depletion of their workforce, which is made up primarily of parents of school-aged children. . Doing everything in our power to keep children in school must remain a priority.

Thank you for your continued leadership during this difficult time and for the immediate steps you have already taken to move New Jersey forward beyond this pandemic. By taking the additional measures described here, we can reduce the impact of the Omicron variant and minimize the disruption it will cause in the weeks to come. I appreciate your consideration.

Truly,

Josh gottheimer

CONGRESSMAN

###

(Visited 24 times, 24 visits today)

Source link

]]>
Top 10 Colleges Offering Fisheries Science Courses to Apply for in 2022 https://vetclinpathjournal.org/top-10-colleges-offering-fisheries-science-courses-to-apply-for-in-2022/ Sat, 08 Jan 2022 07:31:21 +0000 https://vetclinpathjournal.org/top-10-colleges-offering-fisheries-science-courses-to-apply-for-in-2022/
Tamil Nadu Dr. J. Jayalalithaa Fisheries University (TNJFU)

Education is a lifelong endeavor. In India, state agricultural universities are responsible for the education of all agricultural sciences including fisheries in their respective states. The goal of fisheries education is to improve fish production using resources, modern farming systems, using modern harvest and post-harvest techniques, marketing and social progress of the community. of fishermen.

Many students are interested in this field, but they do not know what are all the courses, which can be taken, and from where? To help them get rid of this confusion. Let us tell you that there are currently a number of Undergraduate (UG) and Postgraduate (PG) Fishing Courses available in India which can help shape your future and advance your career. So let’s talk about the 10 best fishing universities in India.

List of Top 10 Fishing Colleges in India:

Below we have listed some of the best fishing colleges in India

Karnataka Veterinarian, University of Animal and Fisheries Sciences, Bidar

KVAFSU (Karnataka University of Veterinary, Animal and Fisheries Sciences) is a state university located in Bidar, Karnataka. KVAFSU, which was founded in 2004, offers a variety of undergraduate (UG) and postgraduate (PG) programs. In addition, the university offers doctoral programs in a variety of specializations at the doctoral level. The application form can be downloaded from the official website of the university.

  • Admission to the BVSc & AH, BFSc and B.Tech courses is granted on the basis of a valid score on the KEA Common Entrance Test (CET).

  • At postgraduate level, the institute also offers M.Tech, MVSc and MFSc courses. Students are admitted to these courses on the basis of their performance in the corresponding baccalaureate and a written test.

  • Admission to the MBA is based on performance on a written test, followed by a group discussion and interview.

  • The university organizes a separate entrance examination followed by an interview for the doctorate. program. Final admission is subject to the applicants’ academic background.

Tamil Nadu Dr J. Jayalalithaa University of Fisheries (TNJFU)

Tamil Nadu Dr. J. Jayalalithaa Fisheries University (TNJFU) is a public fisheries university located in the southern part of Nagapattinam, Tamil Nadu, India. The UG, PG and Ph.D. The courses available in TNJFU are as follows:

UG Course in (TNJFU)

Bachelor of Fisheries Science (BFSc.,), B.Tech (Fisheries Engineering), B.Tech (Biotechnology), B.Tech (Food Technology), B.Tech. (Energy and Environmental Engineering), B.Tech. (Nautical Fisheries Technology), BBA (Fisheries Business Management), B.Voc. (Industrial fish processing technology, B.Voc. (Industrial aquaculture), B.Voc. (Industrial fishing technology), B.Voc. (Aquatic animal health management).

PG course (TNJFU)

Aquaculture, aquatic animal health, aquatic environment management, fisheries economics, fisheries engineering and technology, fisheries extension, fish processing technology, fisheries resource management, fish biotechnology, fish genetics and breeding, nutrition and Fish Food Technology, Fish Quality Assurance Management, Fish Pharmacology and Toxicology, M.Tech (Aquaculture Engineering), M.Tech (Fish Processing Engineering), MBA-Business Management peach.

Doctorate in (TNJFU)

Aquaculture, aquatic animal health, aquatic environment management, fisheries economics, fisheries engineering and technology, fisheries extension, fish processing technology, fisheries resource management, fish quality assurance and management, nutrition and fish feed technology, fish biotechnology, fish pharmacology and toxicology.

Kerala University of Fisheries and Ocean Studies (KUFOS)

Kerala University of Fisheries and Ocean Studies (KUFOS) is the state’s premier university dedicated to fisheries and related studies. It was established by the government of Kerala in 2010. It is an autonomous, state-funded institution headquartered in Panangad, Kochi. The University offers undergraduate, graduate and doctoral programs in Fisheries Sciences.

It also provides a graduate degree in aquarium science and technology, as well as a degree in brackish water and marine aquaculture. The results of the annual entrance examination are used to determine the selection criteria for the different courses.

Dr. Rajendra Prasad Central Agricultural University

Dr Rajendra Prasad Central Agricultural University in Samastipur, Bihar, was founded in 1970. In India, it is renowned for its agricultural engineering courses, research and education. Lord Curzon laid the foundation stone for the university in 1905.

It was established as India’s first Imperial Agricultural Research Institute. Besides the College of Agriculture, Fisheries and Dairy Technology, the university has five faculties in the following disciplines: Agriculture, Veterinary and Animal Sciences, Agricultural Engineering, Basic Sciences, Humanities and Home Sciences and Basic Sciences, Sciences humanities and home sciences. Six undergraduate programs, thirty-three postgraduate programs, and eighteen doctoral programs are available at the university. It is also the only university that offers an MBA in Agribusiness.

Guru Angad Dev University of Veterinary and Animal Sciences (GADVASU)

Guru Angad Dev Veterinary and Animal Sciences University is a veterinary school located in Ludhiana, Punjab. This college is commonly referred to as GADVASU Ludhiana. It was founded on August 9, 2005, with the main aim of promoting animal production in society as well as disseminating knowledge about health and disease prevention through integrated education and extension programs.

The college’s mission is to train graduate veterinarians, scientists and extension workers to promote better livestock health through disease prevention, increased animal production and reproduction, thereby improving the quality of life. rural in Punjab.

Sri Venkateswara Veterinary University (SVVU)

Sri Venkateswara Veterinary University (SVVU) is a state public university located in Tirupati, Chittoor District, Andhra Pradesh, India. It was founded in 2005 by the government of Andhra Pradesh and is dedicated to veterinary studies.

The university offers courses at three levels: undergraduate, graduate and doctorate. Course offerings at SVVU Tirupati include three undergraduate programs, twenty postgraduate programs, and two doctoral programs. BVSc. and animal health, B. Tech Dairy Technology, MVSc. Veterinary surgery and radiology, MVSc. Animal Production Management, MVSc. Veterinary medicine and other courses are available at the university. The university’s Masters of Veterinary Science (MVSc.) Program is available in 17 specializations.

Course duration at Sri Venkateswara Veterinary University ranges from two to six years. Total fees and eligibility requirements for Sri Venkateswara Veterinary University courses vary by program. Full-time courses are available at the university.

College of Fisheries, Mangalore

Mangalore College of Fisheries, Karnataka, is a fisheries education and research institute in India. Bangalore University of Agricultural Sciences founded it in 1969.

The university has two campuses. The main campus, which includes an administrative building, library, departments of aquaculture, fishery microbiology, fishery resources and management, and fishery environment and ecology, as well as hostels (for men and women). women), a training center, guest house, auditorium, sports complex, swimming pool, post office and bank are located on NH 17 in Yekkur, Kankanady, Mangalore.

The Technology Wing is located in Hoige Bazar, near the mouth of the Nethravathy River, near the Arabian Sea, and houses the Departments of Fish Processing Technology and Fisheries Engineering.

Central Institute for Fisheries Education

The Central Institute for Fisheries Education (CIFE) is a reputable university in Mumbai which offers fisheries education. The university offers only two courses in fisheries and agricultural education: MFSc. and Ph.D. The university offers postgraduate (PG) and doctoral education.

The institute is one of four universities recognized by the Indian Council for Agricultural Research (ICAR), along with the Indian Veterinary Research Institute (IVRI), the National Dairy Research Institute (NDRI) and the Indian Institute of agricultural research (IARI).

Maharashtra University of Animal and Fisheries Sciences

Maharashtra University of Animal and Fisheries Sciences (MAFSU) was founded in 2000 and is headquartered in Nagpur, Maharashtra. The University’s constituent colleges include six veterinary colleges, two fishing colleges, two dairy technology colleges, and a wildlife research and training center. The University has been approved by the UGC.

Maharashtra University of Animal and Fisheries Sciences offers undergraduate and graduate programs. In addition, it offers doctoral and diploma programs.

Central Institute for Brackish Water Aquaculture

The Central Brackish Water Aquaculture Institute (CIBA) is one of the research institutes under the Indian Agricultural Research Council (ICAR), New Delhi, which serves as the nodal agency for water aquaculture research brackish in India.

The courses offered at ICAR – Central Institute of Brackish Water Aquaculture are tools for the diagnosis and management of diseases of aquatic animals, diagnosis and control of diseases of brackish water fish and molluscs with a reference particular to emerging diseases, recent advances in soil and water management in brackishwater aquaculture; and Environmental and climate change issues in the sustainability of brackishwater aquaculture.

]]>
Slight pH Adjustment May Turn Metabolic Inhibitor Drug Into Promising COVID-19 Treatment https://vetclinpathjournal.org/slight-ph-adjustment-may-turn-metabolic-inhibitor-drug-into-promising-covid-19-treatment/ Sat, 08 Jan 2022 02:24:00 +0000 https://vetclinpathjournal.org/slight-ph-adjustment-may-turn-metabolic-inhibitor-drug-into-promising-covid-19-treatment/

Professor of Mechanical Engineering and Materials Science David Needham has shown that a slight increase in the pH of the solution might be enough to transform a metabolic inhibitor drug, traditionally used to treat intestinal parasites, into a promising prophylactic / preventative nasal spray and an early throat treatment spray for COVID-19[FEMININE[FEMININE

The results appear online December 28 in the journal Pharmaceutical research.

Since 1958, niclosamide has been used to treat parasitic intestinal infections in humans, pets and farm animals. Supplied as oral tablets, the drug kills parasites on contact by inhibiting their crucial metabolic pathway and cutting off their energy supply.

In recent years, however, researchers have tested the potential of niclosamide to treat a much wider range of diseases, such as many types of cancer, metabolic diseases, rheumatoid arthritis, and systemic sclerosis. Recent laboratory studies in cells have also shown that the drug is a potent antiviral drug, inhibiting a virus’s ability to cause disease by targeting the host cell’s energy supply that the virus co-opts for self-replication. .

Niclosamide acts primarily on the host cell’s mitochondria, which are like energy-producing batteries in the cell. The drug stops the cell from making its main energy molecule, adenosine 5′-triphosphate, or ATP. Without the energy supply to the infected cell, the virus finds it difficult to replicate viable copies of itself to cause other infections. These effects are reversible and do not cause cell death.

“Niclosamide lowers a cell’s energy dimmer and essentially blocks the virus,” said Needham, the sole author of the new study. When used in conjunction with vaccines, masking and other mitigation measures recommended for COVID prevention, the new niclosamide solution has potential as a backup strategy, he said. “This development could enable safe and effective nasal and pharyngeal sprays that provide additional protection behind the mask. “

Pivot in times of pandemic

In an ongoing collaboration with Will Eward, a surgical oncologist at Duke, Needham had previously shown that niclosamide has activity in bone cancer in mice and dogs when turned into a nanoparticle which, as he puts it, , “makes the medicine look like cancer food.” In another collaboration with Christina Barkauskas, assistant professor of medicine in pulmonary medicine at Duke, they were starting preliminary studies on the potential use of the same formulation of niclosamide for pulmonary fibrosis when the pandemic struck.

Like many researchers around the world, Needham has switched to studies led by COVID. After a Korean article examining the effectiveness of existing drugs against COVID-19 identified niclosamide as a potential target, it spent the following year researching a range of solution formulations, nanoparticles and microparticles. Korean studies in animal cells have shown that a low concentration of niclosamide is sufficient before infection to completely stop the replication of the SARS-COV-2 virus.

The animal cells used, however, are extremely tough and durable. To find out how effective and tolerable niclosamide might be for human use to fight COVID-19, Needham and Barkauskas turned to cells that were more relevant for the initial nasal and bronchial infection; respiratory epithelial cells; and hired other clinical researchers from Duke.

With no live virus to test with, the researchers focused on measuring the amount of niclosamide reducing ATP levels in cells of the human airways. Based on the ATP inhibition measurements against the virus from the Korean study, Patty Lee, professor of medicine, cell biology and pathology at Duke, and his postdoctoral fellow Sojin Kim, found that a few micromolar concentrations of the drug can lower ATP levels enough to potentially shut down virus reproduction completely without damaging the cells themselves.

These studies, however, were performed on cells submerged in cell culture media, which slows the rate at which niclosamide is absorbed and can act in cells. In other bench-top cell studies with Barkauskas and Zach Kelleher, a lab technician in his lab, researchers focused on cells in the human airways treated with only niclosamide buffered solution. Funded by a grant from the American Lung Association, the study suggests that even lower doses are enough to positively affect cells in the airways.

But these three studies do not take mucus into account.

The need for reformulation

Traditional allergy medications such as Flonase and Nasonex contain about 6000 to 30,000 times more of their respective active ingredients in solution than it would take to affect cells in laboratory studies. This is because only a small amount of the active drug passes the protective layer of mucus that constantly covers the back of people’s noses and throats.

Niclosamide, however, does not dissolve easily in water-based liquids that can be sprayed into a person’s nose and mouth. The normal attainable solution concentration of the drug at a nasal pH of about 6 or 7 is near or even lower than what laboratory studies suggest is necessary to prevent the virus from replicating in cells without protective mucus.

Based on calculations of how molecules like niclosamide diffuse through a thin layer of mucus, Needham estimates that a solution concentration about 10 times greater than that which can usually be achieved is required to produce a prophylactic spray and treatment function, and that it can pass through the mucus layer in milliseconds.

The question for Needham, then, was how to achieve this concentration.

PH adjustment

In the new article, Needham demonstrates that it is enough to increase the alkalinity of the solution to cross the mucous barrier and enter the cells where a COVID-19 infection first sets in. He found that raising the pH of the solution to a slightly alkaline pH of 8.0; acceptable for a nasal spray; can dissolve enough niclosamide to meet the requirements of its calculations. And increasing the pH to 9.2, which is still tolerable for a throat spray, beats that benchmark 10 times more and could be used early in the infection.

While promising, Needham notes, these results have yet to be tested in cells actually infected with COVID-19, as well as such cells protected by a layer of mucus, which requires finding partner laboratories and agencies with the resources. biocontainment and live viruses required.

A protocol for making liter-sized batches that can be filled and sealed into sterile-capped 10ml vials has already been developed in Duke’s Prep Pharmacy by Vincent Gaver, Clinical Research Pharmacist, and Beth McLendon. -Arvik, director of Investigational Drug Services. And in its new patent application, Needham also described a method for extracting niclosamide from commercially available tablets into solution without using organic solvents.

Because it acts on cells rather than the virus, niclosamide may work as a respiratory viral prophylactic agent, not only against COVID-19 and all of its variants, but also against any new virus. Although the vaccines are clearly effective, a nasal preventative would add additional protection. And even if an infection has already set in, this formulation could be used as an early treatment spray for the throat that could stop the viral load from making its way to the lungs, causing the disease’s most devastating effects. “

David Needham, study author

Needham has already applied for a patent and is actively seeking partners from industry, government and infectious disease institutes to help continue clinical trials and commercialization.

Source:

Journal reference:

Needham, D., (2021) The pH dependence of niclosamide solubility, dissolution, and morphology: motivation for potentially universal mucin-penetrating nasal and pharyngeal sprays for COVID19, its variants, and other viral infections. Pharmaceutical research. doi.org/10.1007/s11095-021-03112-x.

Source link

]]>
Mustang Bio announces targeted CAR T data for the MB-106 CD20 https://vetclinpathjournal.org/mustang-bio-announces-targeted-car-t-data-for-the-mb-106-cd20/ Fri, 07 Jan 2022 19:05:00 +0000 https://vetclinpathjournal.org/mustang-bio-announces-targeted-car-t-data-for-the-mb-106-cd20/

WORCESTER, Mass., Jan. 7, 2022 (GLOBE NEWSWIRE) – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs into therapies cells and genes in potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim phase 1/2 data on MB-106, an autologous CAR T cell therapy targeted against CD20 for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma (“NHL”) and chronic lymphocytic leukemia (“CLL”), were selected for poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings ‘American Society of Transplantation and Cellular Therapy (“ASTCT”) and the Center for International Blood & Marrow Transplant Research (“CIBMTR”), which will take place February 2-6, 2022 in Salt Lake City, Uta h (“2022 Tandem Meetings”). MB-106 is being developed as part of a collaboration between Mustang and the Fred Hutchinson Cancer Research Center (“Fred Hutch”).

Manuel Litchman, MD, President and CEO of Mustang, said, “The compelling clinical activity and favorable safety profile that MB-106 continues to demonstrate in the ongoing Phase 1/2 trial in Fred Hutch demonstrate its potential as an outpatient treatment for patients with relapsed or refractory non-Hodgkin’s B-cell lymphoma and chronic lymphocytic leukemia. We look forward to the updated data that will be presented by Fred Hutch at the 2022 Tandem Meetings, particularly for patients with diffuse large B-cell lymphoma and Waldenstrom’s macroglobulinemia. We also look forward to advancing our targeted CAR T cell therapy program MB-106 CD20 to a multi-center trial as part of the IND of Mustang during the current quarter.

The details of the presentation are as follows:

Title: High efficacy and low toxicity of MB-106, a third generation CD20 targeted CAR-T for the treatment of B-NHL and relapsed / refractory CLL
Poster Number: 225
Dates and times: Thursday February 3 from 6:45 p.m. to 8:15 p.m. and Saturday February 5 from 6:15 to 7:45 p.m.
Presenter: Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutch, Seattle, WA; Physician at Seattle Cancer Care Alliance; Associate Professor, Division of Medical Oncology, University of Washington School of Medicine

For more information, please visit the Tandem Meetings 2022 website at https://na.eventscloud.com/ehome/644055/1151300/.

Note: Fred Hutch scientists played a role in the development of these discoveries, and Fred Hutch and some of his scientists may benefit financially from this work in the future.

About MB-106 (CD20 Targeted CAR T Cell Therapy)
CD20 is a membrane-integrated surface molecule that plays a role in the differentiation of B cells into plasma cells. The CAR T was developed by Mustang research collaborator Fred Hutch in the labs of the late Oliver Press, MD, Ph.D., and Brian Till, MD, associate professor in the clinical research division of Fred Hutch, and licensed exclusively from Mustang in 2017. The lentiviral vector drug substance used to transduce patient cells to create the MB-106 drug product produced at Fred Hutch has been optimized as a third generation CAR derived from fully antibody. human, and MB-106 is currently in a phase 1/2 open-label dose escalation trial in Fred Hutch in patients with B-NHL and CLL. The same lentiviral vector drug produced at Fred Hutch will be used to transduce patient cells to create the MB-106 drug product produced at Mustang Bio’s cell processing facility in Worcester, MA, for administration as part of the multicenter phase 1/2 clinical trial slated to be launched shortly as part of Mustang Bio’s IND. It should be noted that Mustang Bio made minor improvements to its cell treatment to facilitate a possible commercial launch of the product. In addition, prior to commercial launch, Mustang Bio will replace the lentiviral carrier drug substance Fred Hutch with a carrier produced by a commercial manufacturer. Additional information about the trial is available at http://www.clinicaltrials.gov using the identifier NCT03277729.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or acquiring an interest, to fund research and development, and to license or bring the technologies to market. Mustang has partnered with leading medical institutions to advance the development of CAR-T therapies for multiple cancers, as well as lentiviral gene therapies for severe combined immune deficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the United States Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward-looking statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, without limitation, any statement relating to our growth strategy and product development programs and any other statements which are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and the value of our shares. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks linked to the results of research and development activities; risks associated with the timing of the start and end of clinical trials; uncertainties related to preclinical and clinical trials; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the initial stage of products under development; our need for substantial additional funds; government regulations; patent and intellectual property issues; competetion; as well as other risks described in our filings with the SEC. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except as required by law, and we claim safe harbor protection for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company details :
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com

Media Relations Contact Person:
Tony plohoros
6 degrees
(908) 591-2839
tplohoros@6degreespr.com

Source link

]]>
Nordic Lab and TENAK: revolutionizing cold storage technology https://vetclinpathjournal.org/nordic-lab-and-tenak-revolutionizing-cold-storage-technology/ Fri, 07 Jan 2022 10:31:57 +0000 https://vetclinpathjournal.org/nordic-lab-and-tenak-revolutionizing-cold-storage-technology/

In this eBook, Nordic Lab and TENAK, industry pioneers in cold storage solutions for the medical industry, illustrate how their innovative range of cold chain technologies ensure optimal performance for laboratories and medical environments.

While the effects of the COVID-19 pandemic still permeate the world, the need for cutting-edge and robust cold chain technologies has never been greater. As a result, science has embarked on one of the greatest crusades in modern medicine as it strives to defeat the deadly SARS-CoV-2 virus, a battle that requires specialized equipment. For example, the transport and storage of vaccines, virus samples and Covid tests requires specialized cold storage technology, equipment that Nordic Lab and TENAK can expertly supply.

About companies

Nordic laboratory is based in Denmark. The company has positioned itself as a premier manufacturer and distributor of advanced low-temperature freezers, providing hospitals, laboratories and research institutes with state-of-the-art cold storage equipment with exceptional durability and quality that requires little waste. interview.

Founded in 2002, TENAK develops cryo-storage racks and boxes specially designed to be compatible with the main cold storage technologies on the market, including ULT and LN2 freezers. The company’s nearly two decades of experience make it the destination of choice for the cold chain requirements of the medical sector.

A plethora of medical freezers

Nordics Lab has one of the most comprehensive catalogs of high-tech cold storage options on the market, ensuring freezer storage designed to suit storage time, sensitivity and sample type. varied. Their freezing technologies cover temperatures from -10 ° C to -86 ° C and are composed of a single-stage compressor infrastructure that allows them to create small units with large storage capacity.

In addition, respect for the environment, a natural refrigerant, cyclopentane insulation and recyclable materials make Nordic Lab a green alternative. The production complies with ISO 9001, 14001 and 45001 certifications and standards, ensuring uniform and constant high quality.

Innovative cryostorage

Identifying the racks and boxes that work perfectly with freezers can be a challenge in the medical industry, a daunting task that is eradicated with TENAK products. Not only does the company manufacture its ultra-low temperature cold storage racks and boxes to suit major freezers, but its informative selection guide and usage chart give the customer additional assurance that the desired product is 100%. % compatible.

All of TENAK’s cryo-storage racks are manufactured in its factory near Copenhagen, Denmark and are built around three pillars: design, functionality and quality.



Recommended related articles





Source link

]]>
Percheron Capital invests in Animal Dermatology Group, the largest group specializing in veterinary dermatology in the United States https://vetclinpathjournal.org/percheron-capital-invests-in-animal-dermatology-group-the-largest-group-specializing-in-veterinary-dermatology-in-the-united-states/ Thu, 06 Jan 2022 12:00:00 +0000 https://vetclinpathjournal.org/percheron-capital-invests-in-animal-dermatology-group-the-largest-group-specializing-in-veterinary-dermatology-in-the-united-states/

SAN FRANCISCO and IRVINE, Calif., January 6, 2022 / PRNewswire / – Percheron Capital (“Percheron”), a private equity firm focused on partnering with high quality essential service companies, today announced the acquisition of a controlling stake in Animal Dermatology Group , Inc. (“ADG”), the largest group of veterinary dermatologists in the United States As part of the transaction, ADG’s management team will continue to lead the company and the founders and veterinarians of ‘ADG will retain a significant stake in the business.

Along with this investment, ADG completed the acquisition of Animal Dermatology and Allergy Specialists (“ADAS”), a leading veterinary dermatology firm founded by Dr. Andrew Rosenberg, DACVD, at the service of New York Metropolitan area. With this addition, ADG’s specialist veterinary dermatology services now expand to 12 states across the country. Financial terms of the transactions were not disclosed.

ADG was founded in 1980 with a mission to provide the highest quality veterinary dermatological care to pet owners everywhere. The company has since grown into the largest U.S. group of veterinary dermatology specialists engaged in the diagnosis and treatment of acute and chronic skin conditions in companion animals, with more than 40 primary and satellite sites in the United States and the United States. foreigner. ADG also operates the largest American College of Veterinary Dermatology (ACVD) qualified dermatology residency training program in the United States, supporting the development of future dermatologists through comprehensive training and research. The company expects to build on its momentum and significant growth over the next several years, as the growing demand for high-quality veterinary dermatology services increases along with favorable industry winds, including increasing demand. number of pet owners.

Chris collins, co-founder and CEO of Percheron, commented: “We are delighted to partner with ADG to continue to develop the largest veterinary dermatology group in the country. There is a significant demand among pet owners for specialized skin care and ADG has built a network of the industry’s leading dermatologists to meet this need. We look forward to supporting ADG’s talented team as they continue to grow, innovate and provide the highest quality pet care across the country.

Dr. Craig griffin, ADG Co-Founder, said, “We founded ADG with a mission to make cutting-edge veterinary dermatology available to pet owners everywhere. We believe that we are at a natural inflection point in our history of growth, and this partnership with Percheron Capital allows us to take ADG to the next level and bring our innovative services to new and existing markets in order to support and caring for more pets and pet owners. ”

Dr. Wayne Rosenkrantz, co-founder of ADG, added, “We are incredibly proud of our team of physicians and ADG support staff for their commitment to medical excellence, innovation and expansion that make us a leader in veterinary dermatology. – markets in demand, such as the North East through our recent acquisition of ADAS, we are delighted to have a leading partner in Percheron Capital who shares our vision for growth and our commitment to excellent service.

Steven mrha, Chairman and CEO of ADG, said: “As we envision the next chapter in ADG’s evolution, we can’t think of a better partner than Percheron Capital. Their support and resources will allow us to continue to invest in our best physicians, support staff and cutting edge residency program, and accelerate our expansion organically and through acquisitions. “

About Percheron Capital
Percheron Capital is a private equity firm focused on partnering with exceptional teams to build market-leading service companies. The firm’s goal is to help high-quality companies accelerate their growth and increase their long-term value. Percheron manages more $ 850 million committed capital and focuses on investing in strong service companies in resilient end markets including animal health, automotive, education, food and beverage, health and wellness and the residential. For more information, please visit www.percheroncapital.com.

About the Animal Dermatology Group
Animal Dermatology Group (“ADG”) is the largest veterinary dermatology company in the United States, providing the highest quality care to pets with acute and chronic skin conditions. ADG has more than 40 primary and satellite sites where its veterinary dermatology specialists are actively involved in the provision of clinical care, research and academic training. For more information, please visit www.animaldermatology.com.

Media contacts
Percheron capital
Woomi yun / Erik Carlson
Joële frank, Wilkinson Brimmer Katcher
(212) 355-4449

SOURCE Percheron Capital

]]>
Why some cases lead to rapid decline and death https://vetclinpathjournal.org/why-some-cases-lead-to-rapid-decline-and-death/ Thu, 06 Jan 2022 01:09:08 +0000 https://vetclinpathjournal.org/why-some-cases-lead-to-rapid-decline-and-death/ An international team led by Case Western Reserve University School of Medicine has made a significant breakthrough in understanding why Alzheimer’s disease progresses so rapidly in some people that they die within three years.

Researchers found link between misshapen and rapidly replicating strains of tau protein and accelerated cognitive decline – a critical finding that sheds light on variations in Alzheimer’s disease and may help lead to more accurate diagnoses and therapies targeted.

Such work could lead to changes in the management of Alzheimer’s disease, potentially offering patients and families a more precise prognosis.

“For the first time, we have established the link between the behavior of the tau protein in the test tube and the clinical duration of the disease in patients,” said Jiri Safar, professor in the departments of pathology, neurology and Case neuroscience. Western Reserve School of Medicine. “What the research generally says is that Alzheimer’s disease is not a single disease. There is a spectrum and different cases have distinct biological drivers of progression – and they should be treated as diseases. distinct. “

Their findings appeared on January 5 in Science Translational Medicine.

“We have to understand the disease and then categorize it into the different subsets or categories,” Safar said, “and that is indeed where we are now with Alzheimer’s disease.”

Safar’s co-authors include CWRU colleagues Alan Lerner, professor of neurology, and Mark Cohen, professor of pathology and neurology; David Westaway, professor in the Department of Medicine at the University of Alberta and director of its Center for Prions and Protein Folding Diseases; and Rohan de Silva, professor of molecular neuroscience at the Queen Square Institute of Neurology at University College London.

Safar hopes the research will help dispel the public perception that people with Alzheimer’s disease are likely to decline slowly over eight to ten years; 10 to 30% have the rapidly progressive form of the disease.

“We’re talking about 600,000 to 1.8 million patients in the United States alone,” he said. “So now we can think of it the same way we clinically treat malignant tumors like breast cancer or lung cancer – that different cancers have very different prognoses and treatment strategies.”

The next step is to translate the tools used in the study into clinical practice and identify those at high risk for rapid disease progression, then tailor treatments to the diagnosis.

Alzheimer’s disease research follows Safar’s groundbreaking work on prion proteins. He and his colleagues have found that when prions are folded incorrectly, they can replicate and damage the brain. They used concepts and tools developed in the prion work to study the mechanisms of misfolded proteins and applied them to the tau protein and Alzheimer’s disease.

Prion research has helped create a new paradigm for understanding Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

They knew that genetic and environmental factors linked to the increased risk of developing Alzheimer’s disease explained about 30% of cases. In recent research, they have sought to understand the remaining 70%.

The study

Scientists looked at brain samples from 40 people who died of Alzheimer’s disease – about half had slowly lost cognitive functions over the years and the rest declined rapidly and died within three years.

The researchers found that in the rapidly evolving cases, the nuclei of the tau protein particles had a different shape, meaning they had different structural organizations. Additionally, using processes they developed previously, they found that these misfolded tau species – like prions – can replicate faster in test tubes. They also deepened their understanding of the impacts of different structures and characteristics of abnormal tau and determined the attributes that predicted the rate of replication.

Source link

]]>